day voiding diary, and urinary flow rate and post-voiding residual urine volume before and after its administration.
INTRODUCTION AND OBJECTIVES: Implantation of the artificial urinary sphincter (AUS) around the bladder neck (or prostate in men) remains the goldstandard treatment for women with refractory sphincter weakness incontinence (SWI) or patients with neuropathic pathology. This study evaluates long-term outcomes of the AMS800 device in this patient population.
METHODS: Over a 20 year period (January 1995 -December 2014), 140 bladder neck (BN) AUS were implanted in 111 patients (mean age 39.1 years) by a single surgeon. Aetiology of incontinence: Spina bifida n¼53, neuropathic (other) n¼15, failed female incontinence surgery n¼22, pelvic fracture n¼18, extrophy/epispadias n¼15, following undiversion cystoplasty n¼6, other n¼4. 73 were primary procedures, 18 revision after previous infection/erosion and 49 replacement for malfunction. Mean follow-up was 112.8 months (range 12.4 -243.7 months) .
RESULTS: 55 of 140 (39.3%) devices were explanted at a mean of 39.1 months; 26 for erosion (50.4 months), 22 for malfunction (65.1 months), 7 for infection (1.5 months). 30 of 73 (41.1%) primary, 8 of 18 (44.4%) revision and 17 of 49 (34.7%) replacement implants were explanted. 118 devices were implanted in a single stage (n¼51, 43.2% explanted) while 22 were done as a staged procedure (n¼4, 18.2% explanted). In 68 cases patients performed self catheterisation (ISC) with the device explanted in 25 (37.3%) compared to 30 of 72 (41.4%) with no ISC. Interestingly, with ISC there was a much lower rate of erosion then no ISC (10% vs 26%) but a much higher malfunction rate (24% vs 8%). Cystoplasty was present in 67 cases of which 26 (38.8%) were explanted compared to 73 with no cystoplasty in which 31 (42.3%) were explanted. 85 devices (66.6%) remain in situ (42 primary, 10 revision, 33 replacement). 78 (91.8%) are keeping their users continent and happy with the outcome of their surgery. 2 of these, done as a staged procedure, are continent with only the cuff in situ. The other 7 are incontinent due to failure of the surgery or de novo detrusor overactivity.
CONCLUSIONS: Apart from being more surgically challenging, implantation of a bladder neck AUS is associated with excellent functional outcomes albeit with a significantly higher explantation rate when compared to bulbar AUS. Contrary to what we have previously demonstrated with bulbar AUS, we have hereby shown no difference in explantation rate between primary and nonprimary bladder neck AUS. The overall explantation rate is no difference whether a cystoplasty is present or not or whether patients performing ISC. ISC is nonetheless associated with a significantly higher rate of device malfunction. (PTNS) has been successfully used to treat symptoms of overactive bladder(OAB). PTNS currently relies on episodic stimulation of the tibial nerve once/week for 30min in an outpatient setting using an acupuncture needle and a ground pad to create electrical stimulation. We investigated CTNM in OAB patients using this new minimal invasive chronic implantable device (Stim-Guard LLC).
Source of
METHODS: In 2014, two male patients (82y old with Parkinson's disease for 6y and 69y old with MS for 16 years) with neurogenic lower urinary tract dysfunction (nLUTD) received those implants. Both patients suffered from refractory UI and nocturia; detrusor overactivity and detrusor sphincter dyssynergia. In February-April 2016, six additional patients (1 male: spina bifida; 5 female: iOAB) received the implants through a <5mm skin incision. Patients were asked to use the device while sleeping (max 8h). Patients were followed with bladder diary, maximum flow rate (ml/sec), post void residual (PVR) and questionnaires on a regular basis (1 month prior to surgery and 2, 4 weeks, 3 and 6 months postop).
RESULTS: Implantation of the electrode was well-tolerated by all patients and performed as an outpatient procedure without perioperative complication. The initial two patients reported significant e1264 THE JOURNAL OF UROLOGY â Vol. 197, No. 4S, Supplement, Tuesday, May 16, 2017 improvement of nLUTD within 48 hours. Both neurogenic patients were completely dry two months post-op; UI and nocturia disappeared (bladder diary). Both patients stopped CTNM due to the progression of their comorbidity, though a causal correlation could not be drawn. After 1.5 years the electrode of one patient migrated through the implantation path. In the second group, the male was excluded due to lack of improvement and required an alternative treatment. Five female iOAB patients documented major improvements in their bladder diaries. UUI episodes significantly decreased (base: 2.1/day vs. 2.5/month 6 months post-op) and nocturia vanished. Mean voided volume significantly increased by 70ml, without or increased PVR. In the five iOAB patients, all implants are currently in place and their efficacy confirmed. CONCLUSIONS: CTNM offers a promising treatment option using a novel chronic implantable device using an external charger. The new minimalinvasive technology might revolutionize neuromodulation and offers those patients suffering from refractory OAB an opportunity to perform CTNM over several hours, even while sleeping with low or no stimulation related morbidities.
Source of Funding: StimGuard supplied the stimulation devices.
PD64-12
URODYNAMIC FINDINGS OF PATIENTS WITH BRAIN TUMOR CLASSIFIED BY LOCATION OF AFFECTED AREA Hee Seo Son*, Mark Benson Gamo, Jongsoo Lee, Jong Won Kim, Seoul, Korea, Republic of; Sang-Hyeon Cheon, Ulsan, Korea, Republic of; Ju Tae Seo, Jang Hwan Kim, Seoul, Korea, Republic of INTRODUCTION AND OBJECTIVES: With advancement of treatment modalities, the survival of patients with brain tumor has been increased, and the management of lower urinary tract symptom of brain tumor patients emerged as a new challenge. Although several brain imaging studies have been introduced with healthy brain parenchyma, identifying fundamental brain region involved, the correlation of each areas is not proved distinctively. Especially, the effect of intracranial space occupying lesions on bladder and urethra is not clearly demonstrated until now. We have evaluated urological symptoms and urodynamic findings of patients with brain tumor, and made comparison of the urodynamic patterns according the affected brain areas.
METHODS: Brain tumor patients with urological symptom who received urodynamic test at our tertiary referral center from May 2007 to March 2016 were evaluated. To minimize confounding variables, patients with accompanying degenerative neurological disorders, spinal cord injury, diabetes mellitus, prostatic hyperplasia, history of pelvic organ surgery were excluded. And patients with multiple brain lesions were also excluded. The localization of brain tumor was based on the magnetic resonance imaging or computed tomography imaging taken same time of urodynamic study.
RESULTS: Finally, twenty six patients (male 8 female 18) were assessed. The median age at urodynamic study was 46.5 (21.3~76.5) years old. Twenty four patients received urodynamic study at median period of 3.6 (0.9~74.3) months after brain surgery, and two patients had not received operation at the time of urodynamic study. Involuntary detrusor contraction was observed in 13 (50%) patients, acontractile detrusor was observed in 7 (36.9%) patients, and detrusor sphincter dyssynergia was observed only in one patient with frontal lobe tumor. The urological symptom and urodynamic findings showed different pattern according to the affected territory (Figure 1.) CONCLUSIONS: We could observe diverse urodynamic patterns according the affected areas. Our results suggest complexity of micturition circuit in central nervous system. Further study with large cohort in correlation with functional brain imaging might solve the mysterious role of brain on bladder, suggesting management guide according to the affected brain area.
